Older patients with high-risk fungal infections can be successfully allografted using non-myeloablative conditioning in combination with intensified supportive care regimens

被引:26
作者
Hermann, S
Klein, SA
Jacobi, V
Thalhammer, A
Bialleck, H
Duchscherer, M
Wassmann, E
Hoelzer, D
Martin, H
机构
[1] Goethe Univ Frankfurt, Dept Haematol & Oncol, D-60590 Frankfurt, Germany
[2] Goethe Univ Frankfurt, Dept Radiol, D-6000 Frankfurt, Germany
[3] Goethe Univ Frankfurt, Inst Transfus Med, D-6000 Frankfurt, Germany
关键词
high-risk leukaemia; allogeneic bone marrow transplantation; non-myeloablative conditioning; pulmonary aspergillus; granulocyte tranfusions;
D O I
10.1046/j.1365-2141.2001.02747.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Leukaemic patients with advanced disease and severe fungal infections as well as older patients with substantial co-morbidity are usually excluded from conventional allotransplantation because of increased morbidity and mortality. We approached allogeneic transplantation in four patients with a median age of 62 years (one chronic myeloid leukaemia in blast crisis, one high-risk acute myeloid leukaemia (AML) in first complete remission (CR1), one AML in 2nd relapse, one AML in CR2 with pre-existing fungal lung infections (two aspergillus, two mucor) and additional co-morbidity (diabetes n = 2, aortic aneurysm n = 1, arterial sclerosis n = 2) by combining non-myeloablative conditioning with an intensified supportive care regimen, including amphotericin B and 4-12 (median 9) prophylactic granulocyte transfusions from granulocyte colony-stimulating factor (G-CSF)-stimulated volunteer donors. G-CSF was also given to patients until neutrophil recovery All four patients recovered to a neutrophil count of 0.5 x 10(9)/l after a median of 11.5 d (range 11-13 d). Prophylactic granulocyte transfusions also reduced the need for platelet transfusions and minimized mucositis. All patients were discharged at a median of 25 d (range 18-59 d) and are alive and well after a median follow-up of > 390 d (range 336-417 d) without evidence of leukaemia. Regression of the fungal lesions was documented in three patients, with a slight progression detected by computerized tomography scan of the chest in one patient. We conclude that pulmonary fungal infections are not a contraindication for allogeneic stem cell transplantation, if non-myeloablative conditioning regimens are used in combination with granulocyte transfusions, intravenous amphotericin B and G-CSF.
引用
收藏
页码:446 / 454
页数:9
相关论文
共 35 条
  • [1] Transfusions of granulocyte-colony-stimulating factor-mobilized granulocyte components to allogeneic transplant recipients: Analysis of kinetics and factors determining posttransfusion neutrophil and platelet counts
    Adkins, D
    Spitzer, G
    Johnston, M
    Velasquez, W
    Dunphy, F
    Petruska, P
    [J]. TRANSFUSION, 1997, 37 (07) : 737 - 748
  • [2] THE EFFECTS OF DAILY RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR ADMINISTRATION ON NORMAL GRANULOCYTE DONORS UNDERGOING LEUKAPHERESIS
    BENSINGER, WI
    PRICE, TH
    DALE, DC
    APPELBAUM, FR
    CLIFT, R
    LILLEBY, K
    WILLIAMS, B
    STORB, R
    THOMAS, ED
    BUCKNER, CD
    [J]. BLOOD, 1993, 81 (07) : 1883 - 1888
  • [3] GRANULOCYTE TRANSFUSIONS - EFFICACY IN TREATING FUNGAL-INFECTIONS IN NEUTROPENIC PATIENTS FOLLOWING BONE-MARROW TRANSPLANTATION
    BHATIA, S
    MCCULLOUGH, J
    PERRY, EH
    CLAY, M
    RAMSAY, NKC
    NEGLIA, JP
    [J]. TRANSFUSION, 1994, 34 (03) : 226 - 232
  • [4] A second unrelated bone marrow transplant: successful quantitative monitoring of mixed chimerism using a highly discriminative PCR-STR system
    Blau, IW
    Basara, N
    Serr, A
    Seidl, C
    Seifried, E
    Fuchs, M
    Bischoff, M
    Roemer, E
    Fauser, AA
    [J]. CLINICAL AND LABORATORY HAEMATOLOGY, 1999, 21 (02): : 133 - 138
  • [5] EFFECTIVE STIMULATION OF DONORS FOR GRANULOCYTE TRANSFUSIONS WITH RECOMBINANT METHIONYL GRANULOCYTE-COLONY-STIMULATING FACTOR
    CASPAR, CB
    SEGER, RA
    BURGER, J
    GMUR, J
    [J]. BLOOD, 1993, 81 (11) : 2866 - 2871
  • [6] Castagnola E, 1996, BONE MARROW TRANSPL, V18, P97
  • [7] Champlin Richard, 1999, Current Opinion in Oncology, V11, P87
  • [8] Successful treatment of metastatic renal cell carcinoma with a nonmyeloablative allogeneic peripheral-blood progenitor-cell transplant: Evidence for a graft-versus-tumor effect
    Childs, RW
    Clave, E
    Tisdale, J
    Plante, M
    Hensel, N
    Barrett, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (07) : 2044 - 2049
  • [9] CLARKE K, 1995, BONE MARROW TRANSPL, V16, P723
  • [10] Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age
    Deeg, HJ
    Shulman, HM
    Anderson, JE
    Bryant, EM
    Gooley, TA
    Slattery, JT
    Anasetti, C
    Fefer, A
    Storb, R
    Appelbaum, FR
    [J]. BLOOD, 2000, 95 (04) : 1188 - 1194